Molplex develops automated decision‑making systems that use predictive chemistry and biology software to mirror critical choices made by drug development professionals during early stages of discovery and design. The company’s platform is intended to accelerate early‑stage medicinal chemistry by encoding expert decisions into software workflows. Led by CEO David Leahy, Molplex plans to progress a pipeline of early drug projects using its automated systems. The company intends to use recent funding to advance ten early‑stage drug projects through laboratory synthesis and testing. Molplex also plans further updates to its software and to establish a physical base in the North West. The article reports a recent funding event that provides capital to execute those plans.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2012